Copertina

Lessons from COVID‐19: Aspects of prevention, therapeutics, and diagnostics against SARS‐CoV‐2 with special focus on JN.1 and XBB sublineages

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Puja Jaishwal, Upagya Gyaneshwari, Kisalay Jha, Brijesh Pandey, Thakur P. Yadav, Satarudra P. Singh
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	MedComm – Future Medicine
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies
di: Yishan Lu, et al.
Pubblicazione: (2024)

XBB.1.16‐RBD‐based trimeric protein vaccine can effectively inhibit XBB.1.16‐included XBB subvariant infection
di: Dandan Peng, et al.
Pubblicazione: (2024)

Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1
di: Lunzhi Yuan, et al.
Pubblicazione: (2024)

Current clinical findings of acute neurological syndromes after SARS‐CoV‐2 infection
di: Minjin Wang, et al.
Pubblicazione: (2024)

SARS‐CoV‐2 Spike S2 Refolding: Structural Insights and Inhibition Strategies Against Emerging Variants
di: Chen Xu, et al.
Pubblicazione: (2025)

Optimization and validation of a virus‐like particle pseudotyped virus neutralization assay for SARS‐CoV‐2
di: Shuo Liu, et al.
Pubblicazione: (2024)

Development of a SARS‐CoV‐2 neutralization assay based on a pseudotyped virus using a HIV system
di: Ziteng Liang, et al.
Pubblicazione: (2024)

Lycorine Derivative Inhibits SARS‐CoV‐2 Replication by Reducing −1 Programmed Ribosomal Frameshifting via Targeting ZAP
di: Tingfu Du, et al.
Pubblicazione: (2026)

Correction to “Lycorine Derivative Inhibits SARS‐CoV‐2 Replication by Reducing −1 Programmed Ribosomal Frameshifting via Targeting ZAP”
Pubblicazione: (2026)

SARS‐CoV‐2 Spike Protein as a Target of the COVID‐19 Vaccine Disrupts Insulin Signaling in Type 2 Diabetes
di: Lixiang Zhai, et al.
Pubblicazione: (2025)

Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad‐Neutralizing Antibody Response against SARS‐CoV‐2 Omicron Subvariants
di: Guangxu Zhang, et al.
Pubblicazione: (2025)

Ferroptosis: mechanisms and therapeutic targets
di: Qian Zhou, et al.
Pubblicazione: (2024)

Pulmonary fibrosis: pathogenesis and therapeutic strategies
di: Jianhai Wang, et al.
Pubblicazione: (2024)

Rheumatoid arthritis: pathogenesis and therapeutic advances
di: Ying Gao, et al.
Pubblicazione: (2024)

Atopic dermatitis: pathogenesis and therapeutic intervention
di: Chengcheng Yue, et al.
Pubblicazione: (2024)

Point‐of‐care breath sample analysis by semiconductor‐based E‐Nose technology discriminates non‐infected subjects from SARS‐CoV‐2 pneumonia patients: a multi‐analyst experiment
di: Tobias Woehrle, et al.
Pubblicazione: (2024)

Recombinant protein HR212 targeting heptad repeat 2 domain in spike protein S2 subunit elicits broad‐spectrum neutralizing antibodies against SARS‐CoV‐2 and its variants
di: Ying Lu, et al.
Pubblicazione: (2025)

Liver cirrhosis: molecular mechanisms and therapeutic interventions
di: Zihe Dong, et al.
Pubblicazione: (2024)

Anoikis in cell fate, physiopathology, and therapeutic interventions
di: Jie Mei, et al.
Pubblicazione: (2024)

Posttransplant complications: molecular mechanisms and therapeutic interventions
di: Xiaoyou Liu, et al.
Pubblicazione: (2024)

Regulation of bone homeostasis: signaling pathways and therapeutic targets
di: Zebin Wu, et al.
Pubblicazione: (2024)

Tissue‐resident memory T cells in diseases and therapeutic strategies
di: Daoyuan Xie, et al.
Pubblicazione: (2025)

Tumor‐associated exosomes in cancer progression and therapeutic targets
di: Xiaomin Liu, et al.
Pubblicazione: (2024)

Advances in moyamoya disease: pathogenesis, diagnosis, and therapeutic interventions
di: Shihao He, et al.
Pubblicazione: (2025)

Extracellular vesicles in cancers: mechanisms, biomarkers, and therapeutic strategies
di: Yuxi Ma, et al.
Pubblicazione: (2024)

Cellular senescence in cancer: molecular mechanisms and therapeutic targets
di: Ping Jin, et al.
Pubblicazione: (2024)

Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions
di: Lu Zhao, et al.
Pubblicazione: (2024)

Protein palmitoylation: biological functions, disease, and therapeutic targets
di: Yan‐Ran Qian, et al.
Pubblicazione: (2025)

Hypoxia and aging: molecular mechanisms, diseases, and therapeutic targets
di: Ayesha Nisar, et al.
Pubblicazione: (2024)

Lung regeneration: diverse cell types and the therapeutic potential
di: Yutian Chen, et al.
Pubblicazione: (2024)

Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention
di: Li Zhuang, et al.
Pubblicazione: (2024)

Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets
di: Xiangpeng Wang, et al.
Pubblicazione: (2024)

Synthetic circRNA therapeutics: innovations, strategies, and future horizons
di: Jingsheng Cai, et al.
Pubblicazione: (2024)

Cell death pathways: molecular mechanisms and therapeutic targets for cancer
di: Shaohui Wang, et al.
Pubblicazione: (2024)

The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
di: Jian Tang, et al.
Pubblicazione: (2024)

Adenoid cystic carcinoma: insights from molecular characterization and therapeutic advances
di: Yunxuan Jia, et al.
Pubblicazione: (2024)

Heat shock protein 90: biological functions, diseases, and therapeutic targets
di: Huiyun Wei, et al.
Pubblicazione: (2024)

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue
di: Qianqian Li, et al.
Pubblicazione: (2024)

Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targets
di: Shen'er Qian, et al.
Pubblicazione: (2024)

Acute respiratory distress syndrome (ARDS): from mechanistic insights to therapeutic strategies
di: Rongli Xie, et al.
Pubblicazione: (2025)